Holen Sie sich die Stockscreener-App
0.0915
22.98%
-0.0273
Handel nachbörslich:
.09
-0.0015
-1.64%
Schlusskurs vom Vortag:
$0.1188
Offen:
$0.1195
24-Stunden-Volumen:
271.16M
Relative Volume:
4.91
Marktkapitalisierung:
$7.22M
Einnahmen:
$212.10K
Nettoeinkommen (Verlust:
$-40.19M
KGV:
-0.000017
EPS:
-5313.2836
Netto-Cashflow:
$-13.92M
1W Leistung:
+30.71%
1M Leistung:
-25.00%
6M Leistung:
-99.77%
1J Leistung:
-99.94%
1-Tages-Spanne:
$0.0902
$0.133
1-Wochen-Bereich:
$0.0739
$0.158
52-Wochen-Spanne:
$0.0654
$218.00
Aditxt Inc Stock (ADTX) Company Profile
Firmenname
Aditxt Inc
Sektor
Branche
Telefon
909-488-0844
Adresse
737 N. FIFTH STREET, SUITE 200, RICHMOND
Vergleichen Sie ADTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADTX
Aditxt Inc
|
0.0915 | 7.22M | 212.10K | -40.19M | -13.92M | -5,313.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aditxt Inc Aktie (ADTX) Neueste Nachrichten
Aditxt subsidiary Persanta engages Dominary Securities for IPO - TipRanks
Aditxt Co's Unit Pearsanta Engaged Dominari Securities Llc As Lead Underwriter For Pearsanta's Planned IPO - Marketscreener.com
Aditxt subsidiary Pearsanta prepares for IPO with lead underwriter By Investing.com - Investing.com South Africa
Aditxt, Inc Subsidiary Pearsanta Engages Dominari Securities for its IPO By Investing.com - Investing.com South Africa
Aditxt, Inc Subsidiary Pearsanta Engages Dominari Securities for its IPO - Investing.com India
Aditxt subsidiary Pearsanta prepares for IPO with lead underwriter - Investing.com
Can This New DNA Cancer Test Disrupt the $20B Diagnostics Market? Pearsanta Unveils IPO Plans - StockTitan
Microcap Biotech Aditxt Rallies Retail Interest Ahead Of CEO’s Fireside Chat: What’s On Investors’ Radar? - MSN
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
ADTX Stock Earnings: Aditxt Reported Results for Q1 2024 - MSN
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga India
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga
Aditxt, Inc. (NASDAQ:ADTX) Sees Significant Decline in Short Interest - Defense World
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025 - TradingView
Appili Q3 Earnings: Pipeline Success With $14M Funding, FDA Progress, and Take-Private Deal | APLIF Stock News - StockTitan
ADTX stock plunges to 52-week low, touches $0.07 By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ADTX stock plunges to 52-week low, touches $0.07 - Investing.com
Inside Aditxt's Pipeline: CEO Reveals Latest on Type 1 Diabetes Treatment and Cancer Detection Program - StockTitan
Metric Deep Dive: Understanding Aditxt Inc (ADTX) Through its Ratios - The Dwinnex
A stock that deserves closer examination: Aditxt Inc (ADTX) - US Post News
Market cap of Aditxt Inc [ADTX] reaches 7.10M – now what? - The DBT News
Aditxt Inc (ADTX) Stock: A Look at the Analyst Recommendations - The News Heater
Understanding the Risks of Investing in Aditxt Inc (ADTX) - Knox Daily
Aditxt Inc (NASDAQ: ADTX) Could Pass $160 In One Year Stock Forecast - Stocks Register
ADTX’s Market Whiplash: -42.04% YTD Decline, -42.04% Plunge in 30 Days - The InvestChronicle
Aditxt, Inc. (NASDAQ:ADTX) Sees Large Growth in Short Interest - Defense World
Aditx Therapeutics stock hits 52-week low at $0.12 By Investing.com - Investing.com Australia
Aditx Therapeutics stock hits 52-week low at $0.12 - MSN
Aditxt (NASDAQ: ADTX) Board Considers IPO for Subsidiary PearsantaMountain View, CA – January 13, 2025 – Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”) announced today that its Board of Directors has given the green light for exploring the p - Defense World
Aditxt explores IPO for subsidiary Pearsanta in 2025 By Investing.com - Investing.com Canada
Aditxt explores IPO for subsidiary Pearsanta in 2025 - Investing.com India
Aditxt, Inc. Plans IPO for Pearsanta in 2025 - TipRanks
Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform - Quantisnow
Aditx Therapeutics stock hits 52-week low at $0.17 By Investing.com - Investing.com Australia
Aditx Therapeutics stock hits 52-week low at $0.17 - Investing.com
ADTX Stock on the Rise: A Promising Investment - The InvestChronicle
Shares Of Aditxt Inc (NASDAQ: ADTX): Are They Overvalued Compared To Others? - Stocks Register
Aditxt Inc (NASDAQ: ADTX) Inclines 3.78%: This $2.72 million Stock Could Go Down -79900.0% - Stocks Register
Perspective Therapeutics Inc (AMEX: CATX) Could Fell Another -684.31% - Stocks Register
Devon Energy Corp (NYSE: DVN) Stock Forecast: Could Pass $55 In A Year - Stocks Register
No Stopping Energy Transfer LP (NYSE: ET)’s Stock Surged? - Stocks Register
Aditxt, Inc. (NASDAQ:ADTX) Short Interest Down 45.2% in December - Defense World
ADTX stock plunges to 52-week low, touches $0.18 By Investing.com - Investing.com Nigeria
ADTX stock plunges to 52-week low, touches $0.18 - Investing.com
Aditx Therapeutics stock hits 52-week low at $0.31 By Investing.com - Investing.com Canada
Aditx Therapeutics stock hits 52-week low at $0.31 - Investing.com
Aditxt, Inc. (NASDAQ:ADTX) Sees Large Decrease in Short Interest - Defense World
Aditxt Advances ADI-100 Therapy to Human Trials - TipRanks
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials - Quantisnow
Finanzdaten der Aditxt Inc-Aktie (ADTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):